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Introduction
Epidermolysis bullosa (EB) is a group of  genetic diseases characterized by mechanical fragility of  skin and 
mucosa (1). Recessive dystrophic EB (RDEB) is caused by mutations in COL7A1, which encodes type VII 
collagen (C7), the main constituent of  anchoring fibrils at the dermoepidermal junction (DEJ). RDEB is 
one of  the most severe forms of  EB; it is characterized by recurrent blistering, chronic wounds, disabling 
scarring in the skin, and mucosa and internal organ dysfunctions, leading to substantial morbidity and mor-
tality (2–4). Currently, there is no cure for this severe subtype of  EB; however, novel therapeutic strategies 
have been developed in the fields of  gene and cell therapies (5–15).
BACKGROUND. Recessive dystrophic epidermolysis bullosa (RDEB) is an incurable disease that 
causes severe mucocutaneous fragility due to mutations in COL7A1 (encoding type VII collagen 
[C7]). In this phase I/IIa trial, we evaluated the safety and possible clinical efficacy of intravenous 
infusion of allogeneic human umbilical cord blood–derived mesenchymal stem cells (hUCB-MSCs) 
in patients with RDEB.
METHODS. Four adult and two pediatric patients with RDEB were treated with 3 intravenous 
injections of hUCB-MSCs (1 × 106 to 3 × 106 cells/kg) every 2 weeks and followed up for 8–24 months 
after treatment. The primary endpoint was safety. Secondary endpoints related to efficacy included 
clinical parameters, such as disease severity score, wound assessment, itch and pain score, and 
quality of life. C7 expression levels and inflammatory infiltrates in the skin, as well as serum levels 
of inflammatory markers and neuropeptides, were also assessed.
RESULTS. Intravenous hUCB-MSC infusions were well tolerated, without serious adverse 
events. Improvements in the Birmingham Epidermolysis Bullosa Severity Score, body surface 
area involvement, blister counts, pain, pruritus, and quality of life were observed with maximal 
effects at 56–112 days after treatment. hUCB-MSC administration induced M2 macrophage 
polarization and reduced mast cell infiltration in RDEB skin. Serum levels of substance P were 
decreased after therapy. Increased C7 expression was observed at the dermoepidermal junction in 
1 of 6 patients at day 56.
CONCLUSION. To the best of our knowledge, this is the first clinical trial of systemic administration 
of allogeneic hUCB-MSCs in patients with RDEB, demonstrating safety and transient clinical 
benefits.
TRIAL REGISTRATION. ClinicalTrials.gov NCT04520022.
FUNDING. This work was supported by Daewoong Pharmaceutical Co. Ltd. and Kangstem 
Biotech Co. Ltd.
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Mesenchymal stem cells (MSCs) have been identified as an attractive option for allogeneic cell therapy 
for RDEB based on their potential mechanisms of  action, including immunomodulation, migration to 
damaged tissue, stimulation of  tissue regeneration, and reduction of  fibrosis, mainly through paracrine 
activities (8–11, 14–16). Locally injected allogeneic bone marrow–derived MSCs (BM-MSCs) have shown 
to accelerate wound healing, with transient C7 restoration in patients with RDEB and a mouse model of  
dystrophic EB (10). Two early-phase clinical trials of  systemic administration of  allogeneic BM-MSCs in 
23 pediatric patients with RDEB reported variable clinical benefits that lasted for several months with sat-
isfactory safety (8, 9). An additional recently published phase I/II trial of  intravenous BM-MSC injection 
in 10 adult patients with RDEB also showed transient, but clinically meaningful, improvements in disease 
severity, skin inflammation, and pruritus, with no serious adverse events (AEs) (14).
To our knowledge, previous clinical trials for RDEB have examined the potential of  BM-MSCs (8, 9, 
14). However, umbilical cord blood (UCB) has become an attractive source of  stem cells, because of  its 
noninvasive collection procedure and rapid availability from cord blood banking (17, 18). Human UCB-de-
rived MSCs (hUCB-MSCs) exhibit higher proliferation capacity and lower immunogenicity compared with 
BM-MSCs (17, 19). Data from a few reports support that UCB-MSCs may have greater immunosuppres-
sive potential than other sources of  MSCs (17–22). In addition, hUCB-MSCs have shown greater immuno-
suppressive and regenerative potential than BM- or peripheral blood–derived MSCs in murine wounding 
model (23). A preclinical study has demonstrated that repeated systemic infusions of  human UCB-de-
rived unrestricted somatic stem cells, a subpopulation of  nonhematopoietic stromal stem cells, significantly 
extended the life span and reduced blistering in a RDEB mouse model (16). Given the promising results 
of  the preclinical study, we conducted a first-in-human, phase I/IIa clinical trial of  intravenous adminis-
trations of  allogeneic hUCB-MSCs in patients with RDEB to determine safety, tolerability, and potential 
efficacy. We also analyzed changes in serum inflammatory markers, neuropeptides, and skin inflammatory 
infiltrates as well as C7 expression following hUCB-MSC treatment.
Results
Patient characteristics. Between October 2016 and May 2019, 6 patients with RDEB were assessed for eligi-
bility. Three adult and two pediatric patients were sequentially enrolled in the trial and received 3 repeated 
intravenous hUCB-MSC injections. One additional adult patient was treated with the same investigational 
product under the treatment use approval from the Korea Food & Drug Administration (KFDA), because 
they were too late for trial enrollment (Figure 1). All patients had moderate-to-severe or severe phenotypes, 
with various extracutaneous symptoms. Negative or markedly decreased expression of  C7 noncollage-
nous-1 domain was found in baseline skin biopsies. Analysis of  circulating autoantibodies against C7 using 
indirect immunofluorescence (IIF) was negative for all patients (Table 1). All adult patients received 3 × 106 
hUCB-MSCs/kg every 2 weeks, whereas the 2 pediatric patients received 1 × 106 to 2 × 106 hUCB-MSCs/
kg every 2 weeks. All patients were carefully observed for clinical signs and laboratory test results related to 
potential thromboembolic events were monitored, even though a recent meta-analysis of  randomized con-
trolled trials reported no significant increase in the risk of  thromboembolic events for patients treated with 
MSCs as compared with the control group (24). Demographics and clinical characteristics of  participants 
and trial flow are provided in Figure 1 and Table 1. All patients completed at least 8 months (8–24 months) 
of  follow-up after the first infusion.
Safety. AEs during the study period are summarized in Supplemental Tables 3 and 4 (supplemental 
material available online with this article; https://doi.org/10.1172/jci.insight.143606DS1). Overall, 50% 
of  the patients treated reported ≥1 AE. The most frequent AE was wound infection (4 of  13 AEs, 30.8%), 
but all wound infections were thought to be due to the underlying RDEB. Only acute gastritis was con-
sidered as an AE determined to be possibly related to cell therapy. No severe AEs (defined by Common 
Terminology Criteria for Adverse Events) at grade 3 or higher were reported, suggesting that intravenous 
hUCB-MSC injections were generally well tolerated. There were no clinically significant changes in labora-
tory test values, except increased basal levels of  C-reactive protein (CRP) and fibrinogen, vital signs or elec-
trocardiogram results during the study period. There were no changes in tissue-bound immunoreactants 
using IIF following cell therapy.
Clinical efficacy. hUCB-MSC treatment markedly reduced erythema and erosions in patients with 
RDEB (Figure 2). At day 56, the mean clinical severity scores assessed by the Birmingham Epidermol-
ysis Bullosa Severity Score (BEBSS) and total body surface area (TBSA) affected by RDEB significantly 
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decreased by 5.6 points (95% CI, –7.39 to –3.86) and 5.4 points (95% CI, –8.14 to –2.61), respectively. 
Blister count and the ratio of  blister area to body surface area also decreased by 4 points (95% CI, –6.74 
to –1.26) and 2 points (95% CI, –4.02 to –0.06), respectively, at day 56 compared with baseline. After 
day 56, these clinical effects of  hUCB-MSCs were either maintained or slightly attenuated over time 
until day 168 (Figure 3 and Supplemental Figure 1). Chronic nonhealing wounds in RDEB are asso-
ciated with decreased quality of  life (QOL) and increased risk of  cutaneous squamous cell carcinoma 
(cSCC). We evaluated the effect of  hUCB-MSCs on the healing of  chronic open wounds that were 
unhealed for at least 12 weeks with wound size >100 cm2, as defined in a previous study (13). One 
pediatric (subject 4) and one adult (subject 6) subject each had 2 chronic open wounds. Of  the 4 chron-
ic wounds from 2 subjects, 2 wounds (1 from subject 4 and 1 from subject 6) (50%) showed a 50% or 
greater reduction in wound size compared with baseline at day 56. Of  these 2 wounds, only 1 remained 
at least 50% healed by day 112.
hUCB-MSC treatment resulted in a substantial mean reduction in pain (−3 points on visual analogue 
scale [VAS] score, 95% CI, –4.76 to –1.24) and itch (−2 points on VAS score, 95% CI, –3.76 to –0.24) from 
baseline to day 56. Mean VAS scores for pruritus were maintained by day 168, while pain VAS scores 
showed a gradual increase over time (Figure 3). At day 56, QOL, as assessed by a QOL in EB questionnaire 
(QOLEB), was improved by 6.2 points (95% CI, –8.69 to –3.65). The baseline and mean change from the 
baseline for the secondary outcome data are summarized in Supplemental Table 5. As shown in Supplemen-
tal Figure 2, age subgroup analyses (children vs. adults) showed no significant between-group differences in 
the secondary outcomes, including BEBSS, TBSA, blister count and area, itch and pain scores, and QOLEB.
Molecular assays for C7 in skin. Then we evaluated whether systemic infusions of  hUCB-MSCs could 
restore C7 and anchoring fibrils in RDEB skin by immunofluorescence staining and transmission electron 
microscopy (TEM) analysis of  skin of  patients before and after treatment. On day 56, 1 patient (subject 1) 
showed an increase in C7 expression levels at the DEJ, as assessed by mean fluorescence intensity (MFI) 
compared with baseline, while others (subjects 2–6) showed no significant changes in C7 expression in 
skin after MSC treatment (Figure 4). No obvious differences in anchoring fibril structure or distribution 
were observed between baseline and day 56 in all 6 patients, as assessed by TEM (data not shown).
Changes in skin infiltration of  macrophages and mast cells. Macrophages have a central role in maintaining 
tissue homeostasis and repair. Classic proinflammatory (M1) and alternatively activated, antiinflammato-
ry (M2) macrophages exhibit distinct phenotypes and functions (25, 26). Previous studies indicated that 
MSCs can promote M2 polarization of  tissue macrophages, contributing to tissue regeneration (27–29). 
Therefore, we analyzed the phenotypes of  macrophages in the skin of  patients with RDEB before and after 
hUCB-MSC treatment. The number of  CD68+ total macrophages was higher in the skin of  patients with 
RDEB at baseline than in healthy controls. Intravenous administration of  hUCB-MSCs did not affect the 
density of  CD68+ total macrophages but significantly increased macrophages expressing CD206, a marker 
Figure 1. Study design. (A) Flow chart for clinical trial and treatment use (expanded access to investigational drugs for treatment use). (B) Study design for 
hUCB-MSC treatment and evaluation.
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of  M2 macrophages, in RDEB skin at day 56 (Figure 5). Mast cells play a central role in neuroinflamma-
tory pain and itch (30, 31). Baseline skin biopsies of  patients with RDEB showed a significant increase of  
mast cell infiltration compared with normal human skin, but mast cell infiltration was significantly reduced 
56 days after hUCB-MSC treatment (Figure 5).
Changes in systemic inflammatory markers and neuropeptides. Chronic wounds in RDEB trigger system-
ic inflammation that may contribute to multiple-organ damage (2, 3, 32–34). Since MSCs have potent 
immunomodulatory capacities, we investigated the effect of  hUCB-MSC infusion on serum inflammatory 
markers in patients with RDEB. Serum levels of  CRP fluctuated in individual patients over time, but no 
significant change in the mean CRP values was observed 56 days after hUCB-MSC treatment (data not 
shown). Additionally, baseline serum levels of  proinflammatory cytokines, IL-1β and IL-6, were elevated in 
patients with RDEB compared with those in healthy controls, but these levels were not significantly altered 
by hUCB-MSC treatment on day 56 (Figure 6).
Given the remarkable efficacy of  hUCB-MSC treatment in reducing pain and itch in patients with 
RDEB in this study, we also analyzed the changes in serum levels of  neuropeptides. Baseline serum levels 
of  substance P were significantly higher in patients with RDEB compared with age-matched healthy con-
trol values, and, notably, substance P levels were significantly reduced 56 days after hUCB-MSC treatment. 
Serum calcitonin gene–related peptide (CGRP) levels were also higher in patients with RDEB than in 
healthy controls, and these levels were reduced from baseline after hUCB-MSC treatment (P = 0.06), but 
these changes were not statistically significant (Figure 6).
Discussion
This open-label, phase I/IIa clinical trial shows that 3 repeated intravenous administrations of  allogeneic 
hUCB-MSCs are well tolerated and potentially provide clinical benefits by reducing disease severity, dis-
ease-affected body area, blister count, and pain and itch and improving QOL in children and adults with 
moderate-to-severe or severe RDEB. This study is meaningful in that it is the first clinical trial to our knowl-
edge to apply MSCs derived from UCB, systemically, to patients with RDEB.
Three separate intravenous infusions of  hUCB-MSCs did not cause serious AEs. A previous clini-
cal trial of  BM-MSCs in 10 adult patients with RDEB reported development of  cSCC in 2 participants 
about 6–7 months after the injections (14), suggesting careful monitoring of  this potential complication, 
particularly in adult patients. In this trial, of  the 4 adult patients, 1 patient (subject 6) was followed up 
for 16 months, and the remaining 3 patients (subjects 1, 2, and 3) were followed up for up to 24 months; 
Table 1. Demographics and clinical characteristics of 6 patients with RDEB
Subject 1 2 3 4 5 6
Sex/age in yr F/60 F/25 M/21 F/13 F/8 F/28
Race (ethnicity) Asian (Korean) Asian (Korean) Asian (Korean) Asian (Korean) Asian (Korean) Asian (Korean)
COL7A1 mutations
c.3631C > T, 
p.Gln1211*, exon 
27; c.8569G > T, 
p.Glu2857*, exon 116
c.3139+12G > A, 
intron 23; c.5188C 
> T, p.Arg1730*, 
exon 58
c.2005C > T, 
p.Arg669*, exon 
15; c.8569G > T, 
p.Glu2857*, exon 116
c.3631C > T, 
p.Gln1211*, exon 27; 
c.3717_3721delTACTC, 
exon 27




G, intron 22; 
c.3139+12G > A, 
intron 23
Phenotype Severe Moderate to  severe
Moderate to  
severe Severe
Moderate to  
severe Severe
C7 expression at  























Race and ethnicity were classified by investigators. C7, type VII collagen; DEJ, dermoepidermal junction; DIF, direct immunofluorescence test; F, 
female; IIF, indirect immunofluorescence test; M, male; s/p, status after operation. 
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there was no development of  cSCC during these follow-up periods. However, long-term follow-up data 
for more patients is needed to accurately evaluate the potential relationship between allogeneic hUCB-
MSCs therapy and the risk of  cSCC in RDEB.
Although the primary objective was to assess safety, our data provide evidence of  the potential 
efficacy of  hUCB-MSC therapy in various clinical aspects of  RDEB. hUCB-MSC infusions signifi-
cantly reduced disease severity, as assessed by using BEBSS, affected body surface area, blister count, 
and blister area, with a maximal effect at day 56 in most patients. Over time, these clinical effects of  
hUCB-MSCs were progressively attenuated, but some patients showed sustained improvement up to 
day 168. With regard to wound healing, 50% (2 of  4) of  large open wounds that were present for at 
least 12 weeks achieved 50% or greater healing by 56 days after treatment. Despite the small number of  
available chronic large wounds and the lack of  control wounds, based on a previous report that indicat-
ed that a 50% reduction in chronic RDEB wounds is clinically meaningful in terms of  improvement in 
patient-reported outcomes (13), our results indicate that hUCB-MSC therapy exerts beneficial effects 
on wound healing in RDEB. In addition to the improvement of  cutaneous lesions, intravenous admin-
istration of  hUCB-MSCs also relieved the symptom of  dysphagia in 1 patient (subject 3), allowing the 
scheduled balloon dilation for esophageal stricture to be delayed.
Recalcitrant pain and pruritus are among the most bothersome symptoms of  RDEB (35–38). Pain in 
severe generalized RDEB is often very severe in that it does not respond well to potent opioid analgesics, 
and its intensity was shown to be greater than in postherpetic neuralgia (39). RDEB also causes severe pru-
ritus that is thought to be associated with cutaneous inflammation secondary to barrier disruption, wound 
healing processes, and dysregulated activity of  epidermal nerve fibers (38).
In this study, hUCB-MSCs markedly reduced pain and pruritus in patients with RDEB by reducing 
average VAS scores by 3 cm and 2 cm on day 56, respectively. Given that the minimum important differ-
ence for clinical improvement of  chronic pain or pruritus has shown to be 2 to 3 cm on the VAS score (40, 
41), our data suggest that hUCB-MSC treatment is effective in achieving a clinically relevant improvement 
in pain and pruritus in RDEB that may lead to improved QOL.
When comparing the clinical efficacy of  hUCB-MSCs with that of  BM-MSCs in RDEB, the mean 
differences in BEBSS and QOLEB scores at day 56 in our study were 5.6 points (95% CI, –7.39 to 
–3.86) and 6.2 points (95% CI, –8.69 to –3.65), which were comparable to those in previous studies 
using BM-MSCs in children (mean difference of  BEBSS at day 60 was 5.2, QOLEB score was 4.4) and 
adults (mean difference of  BEBSS at day 60 was 1.61, QOLEB score was 3.13) (8, 14). These findings 
indicate that hUCB-MSCs provide comparable therapeutic effects to BM-MSCs in improving disease 
severity and QOL in patients with RDEB. Regarding the itch and pain outcome, it is difficult to directly 
compare the effect of  hUCB-MSCs with that of  BM-MSCs because of  the different measurement tools 
Figure 2. Marked reduction in erythema and erosions after hUCB-MSC treatment. Photographs of a pediatric (A, sub-
ject 4) and an adult patient with RDEB (B, subject 1) at baseline and after 3 repeated injections of hUCB-MSCs.
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in each study and the lack of  data on pain in the previous study using BM-MSCs in adult patients. The 
results of  our trial show that hUCB-MSCs effectively ameliorate pain as well as pruritus in both chil-
dren and adults with RDEB.
When comparing the clinical efficacy of  allogeneic MSCs in pediatric and adult patients with RDEB, 
previous studies reported a better clinical efficacy of  BM-MSCs in children (mean difference of  BEBSS at 
day 60 was 5.2) than in adults (mean difference of  BEBSS at day 60 was 1.61) (8, 14), which was speculated 
to be associated with more severe systemic inflammation and scarring in adults patients with RDEB. In 
contrast, the therapeutic efficacy of  hUCB-MSCs in this trial (mean difference of  BEBSS at day 56 was 
5.13 in children and 7.18 in adults) was similar in children and adults. Considering that the number of  cells 
administered per kilogram of  patient’s body weight was lower in children (3 infusions, each dose 1 × 106 to 
2 × 106 cells/kg) than in adults (3 infusions, each dose 3 × 106 cells/kg) in this trial, additional clinical data 
are needed to accurately compare the effects of  hUCB-MSCs in pediatric and adult patients with RDEB.
Mechanistically, systemic treatment with hUCB-MSCs did not restore the expression of  C7 and 
anchoring fibril at the basement membrane in the skin of  most patients, except for 1, who showed increased 
C7 expression on day 56. These findings are consistent with previous clinical trials of  systemic adminis-
tration of  BM-MSCs (8, 9, 14) and suggest that the therapeutic benefits of  hUCB-MSCs are not primarily 
caused by the recovery of  C7 expression.
The mechanisms underlying hUCB-MSC–mediated therapeutic effects on RDEB are still unknown. To 
understand their mechanisms of  action, we further assessed the changes in blood biomarkers of  inflamma-
tion and innate immune cells infiltration in the skin following hUCB-MSC treatment.
Patients with RDEB showed higher serum levels of  CRP and proinflammatory cytokines, IL-1β and 
IL-6, compared with healthy controls, suggesting systemic inflammation in severe generalized RDEB. 
Despite the reductions in disease severity and cutaneous erythema, serum levels of  CRP, IL-1β, and IL-6 
showed no significant change after hUCB-MSC treatment compared with baseline, suggesting that these 
inflammatory molecules are not suitable biomarkers for monitoring therapeutic response to hUCB-MSCs. 
Figure 3. Systemic treatment with hUCB-MSCs improved clinical symptoms in patients with RDEB. The time course of changes in disease severity (assessed 
by Birmingham Epidermolysis Bullosa Severity Score [BEBSS]), blister count, visual analog scale (VAS) pain score, and VAS pruritus score was assessed through-
out the trial. For each parameter, a graphical representation of mean score per visit with range per visit was added. Two-tailed Student’s t test was performed 
for all the comparisons (n = 6). *P < 0.05. S, subject. Values are shown as the mean ± SEM.
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CRP and IL-6 are markers of  acute phase response, and fluctuating CRP values in individual patients might 
reflect the dynamic inflammatory status in patients with RDEB. Our findings are consistent with those of  a 
prior clinical trial of  BM-MSCs in patients with RDEB, which reported that inflammatory molecules were 
generally unchanged, but high mobility group box-1 was significantly decreased after treatment (14, 32).
To date, little is known about the pathophysiological mechanism of pain and pruritus in RDEB, but recent 
study found a decreased nerve fiber density and increased number of  activated mast cells in skin of  patients 
with RDEB, indicating neuropathic pain and itch (42, 43). Sensory nerve-derived neuropeptides, substance P, 
and CGRP participate in neuroimmune crosstalk, thereby leading to neurogenic inflammation, neuropathic 
pain, and itch (30, 31). Moreover, the substance P-neurokinin 1 receptor antagonists have been reported to 
effectively reduce pruritus in patients with prurigo (44), cutaneous T cell lymphoma (45), and EB (46).
Interestingly, serum substance P levels were significantly higher and serum CGRP levels tended to be 
higher in patients with RDEB compared with those in healthy controls. In addition, serum substance P and 
CGRP levels were reduced after hUCB-MSC treatment. Consistent with a previous study (42), increased 
numbers of  mast cells were detected in the skin of  patients with RDEB compared with healthy skin at 
baseline. Of  note, infiltration of  mast cells was substantially reduced after hUCB-MSC treatment. These 
findings suggest the possible role of  substance P and mast cells in the neuropathic pain and itch in patients 
with RDEB. Furthermore, the effective attenuation of  pain and pruritus in hUCB-MSC–treated patients 
with RDEB could be due to the inhibition of  substance P levels and mast cell activation.
Figure 4. Systemic treatment with hUCB-MSCs does not significantly affect the expression levels of C7 at the DEJ 
in most patients, except for in 1 patient (subject 1), who showed an increase in C7 expression at day 56. (A) Repre-
sentative immunofluorescence staining for type VII collagen (C7) using LH7.2, a monoclonal antibody that recognizes 
the NC1 domain of C7, on skin biopsy samples obtained before treatment (baseline) and at day 56 from patients with 
RDEB (subjects 1 and 5) receiving hUCB-MSC treatment. Scale bars: 20 μm. White arrows indicate C7 expression at the 
dermoepidermal junction (DEJ). (B) The intensity of staining for C7 expression along the DEJ was morphometrically 
quantitated as MFI using ImageJ (NIH). Values are shown as the mean ± SEM.
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Another interesting aspect of  this work is the evaluation of  changes in macrophage phenotype fol-
lowing hUCB-MSC treatment. Macrophages play an important role in immune modulation, tissue repair, 
and fibrosis (25, 26). In this study, we found that hUCB-MSC treatment did not alter the number of  total 
macrophages but markedly increased M2 macrophage infiltration in the skin of  patients with RDEB. These 
findings are consistent with observations from a preclinical study of  human UCB-derived nonhemato-
poietic stromal stem cells in RDEB mouse model (16), supporting that hUCB-MSC therapy–induced M2 
polarization of  tissue macrophages also occurs in patients with RDEB. The increase in these prorepair or 
alternatively activated M2 macrophages might contribute to accelerated wound healing and the resolution 
of  inflammation following hUCB-MSC treatment; however, further studies are necessary to elucidate the 
functional significance of  macrophage M2 polarization.
In addition to studies of  allogeneic MSCs from UCB or bone marrow, there has been an ongoing 
clinical trial using allogenic ABCB5-expressing MSCs (ABCB5+ MSCs) in patients with RDEB (Clini-
calTrials.gov NCT03529877) since January 2019. Recently, human dermal ABCB5+ MSCs have emerged 
as a promising novel therapeutic candidate for the treatment of  various incurable diseases, with their 
Figure 5. hUCB-MSC treatment modulates macrophage phenotype and mast cell infiltration in skin from patients with RDEB. (A) Representative immu-
nofluorescence staining for total macrophages (CD68), CD206+ macrophages, and mast cells (c-kit) on skin biopsy samples before treatment (baseline) and 
at day 56 for 6 matched pairs of patients with RDEB receiving hUCB-MSC treatment. Scale bars: 50 μm. (B) Mean total numbers of skin-infiltrating cells 
in biopsies from healthy controls (HCs) and RDEB skin at day 0 and at day 56 following hUCB-MSC treatment. By day 56, hUCB-MSC treatment markedly 
increased CD206+ macrophage counts and reduced mast cell counts. Values are shown as the mean ± SEM. Wilcoxon’s signed-rank test was performed for 
all the comparisons (n = 6). ***P < 0.001. S, subject.
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immunomodulatory effects and safety (47). In addition, there is growing evidence that MSC-derived 
extracellular vesicles augment the therapeutic potential of  MSCs in various pathways (48, 49). Especially 
in RDEB, MSC-derived extracellular vesicles can support the transport of  C7 within the extracellular 
space and provide fibroblasts with mRNA encoding C7 (50). Taken together, in addition to hUCB-MSCs 
and BM-MSCs, human dermal ABCB5+ MSCs or MSC-derived extracellular vesicles also can be alterna-
tive therapeutic candidates in the field of  cell therapy for RDEB.
The limitations of  this open-label study included the small number of  patients and the lack of  a control 
placebo-treated arm.
In conclusion, allogeneic hUCB-MSCs were well tolerated when administered intravenously 3 times 
in both pediatric and adult patients with RDEB. hUCB-MSC therapy reduced disease severity, with sig-
nificant improvements noted in erythema in the affected area, blister count, pain, pruritus, and QOL. In 
addition, transient clinical benefits of  allogenic hUCB-MSCs were observed, with a maximal efficacy at 
56–112 days after treatment and a gradual attenuation of  these clinical benefits through day 168. In the 
future, larger clinical trials are needed to investigate the optimal dosage, number of  injections, differential 
efficacy of  different tissue-derived MSCs, and the long-term safety of  allogeneic MSC therapy for RDEB.
Methods
Patients, study design, and procedures. This phase I/IIa, single-center, nonrandomized, open-label trial to eval-
uate the safety and efficacy of  hUCB-MSCs for patients with RDEB was conducted at Gangnam Severance 
Hospital. The diagnosis of  RDEB was made by immunofluorescence antigen mapping, TEM, and muta-
tion analysis of  the COL7A1 gene. Detailed criteria for patient recruitment are described in Supplemental 
Table 1. Patients who provided informed consent were screened within 4 weeks before the start of  the cell 
therapy. The visit schedule consisted of  a 4-month run-in period that included a screening visit and an 
enrollment visit, 3 administrations of  hUCB-MSCs, and an 8- to 24-month follow-up period (Supplemental 
Table 2). Patients received 3 separate intravenous injections of  hUCB-MSCs every 2 weeks and then were 
assessed at days 56, 112, and 168 and 8–24 weeks after treatment. Following the first administration of  
hUCB-MSCs, the patients remained hospitalized for 24 hours for observation of  possible AEs. Peripheral 
blood samples were obtained at each visit for safety laboratory tests and biomarkers analysis. Skin biopsy 
Figure 6. hUCB-MSC treatment reduces serum substance P levels in 
patients with RDEB. Serum levels of inflammatory cytokines (IL-1β 
and IL-6) and neuropeptides (substance P and CGRP) were assessed 
in healthy controls (HCs) and patients with RDEB (n = 6) at baseline 
and at day 56 following hUCB-MSC treatment. Values are shown as 
the mean ± SEM. Wilcoxon’s signed-rank test was used to assess the 
statistical difference between the repeated measurements in the same 
patient. *P < 0.05. S, subject.
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samples obtained at visits 1 and 5 were examined for changes in C7 and anchoring fibril expression by 
immunofluorescence staining and TEM, respectively, and skin infiltration of  immune cells after treatment. 
Study design, with schedules, is described in Supplemental Table 2.
Production of  hUCB-MSCs. hUCB-MSCs were manufactured and expanded according to good manufac-
turing practice (GMP) regulations. hUCB-MSCs from UCB of  healthy donors were isolated and expanded 
with the KSB-3 Complete Medium Kit (Kangstem Biotech Co. Ltd.) at the GMP facility of  Kangstem 
Biotech Co. Ltd. The manufactured cells were confirmed to meet the quality control criteria approved by 
the Ministry of  Food and Drug Safety.
Outcome measures. The primary endpoints of  the investigation were the safety and tolerability of  3 sep-
arate intravenous administrations of  hUCB-MSCs. Safety was assessed through the monitoring of  AEs, 
laboratory assessments, vital signs, electrocardiograms, and abbreviated physical examinations at each visit 
during the 8- to 24-month period after treatment. Secondary efficacy endpoints included (a) disease severity 
scores assessed by BEBSS and TBSA affected by EB; (b) wound assessment by clinical photograph, blister 
count, and the ratio of  blister area to body surface area; (3) VAS for pain and pruritus; and (4) QOLEB 
during the 6-month period after treatment compared with those in the screening period.
Immunofluorescence staining and TEM analysis. Frozen skin tissues from the patients were sectioned at 
5 μm and stained with primary antibodies, including mouse monoclonal [LH7.2] antibodies against C7 
(ab6312; Abcam), mouse monoclonal antibodies against CD206 (321102, Biolegend), mouse monoclonal 
antibodies against CD68 (ab955, Abcam), and rabbit polyclonal antibodies against c-kit (A4502, Dako). 
Alexa Fluor 488–conjugated rabbit anti-mouse IgG and goat anti-rabbit IgG (both from Thermo Fisher 
Scientific) were used as secondary antibodies. Sections were stained with DAPI (Thermo Fisher Scientific). 
Images were captured using an LSM 780 confocal microscope (Carl Zeiss). Negative controls omitting the 
primary antibody were also performed (data not shown). The skin tissue sections were fixed in Karnovsky’s 
fixative and examined under a TEM (H-7600, Hitachi).
MFI. MFI was calculated for each immunofluorescence stained image for C7 using ImageJ (NIH). Five 
measurements were taken at regular intervals using 8 × 8 pixels every 100 pixels along the dermal-epider-
mal junction. The values are presented as mean ± SEM.
IIF. The detection of  circulating anti-C7 autoantibodies was performed in all patients by an IIF study 
performed on salt-split normal human skin substrate. To evaluate the presence of  anti-C7 antibodies, 
patient serum was obtained at baseline, day 56, day 112, and day 168 for evaluation of  anti-C7 antibodies 
by salt-split IIF.
Serum biomarkers measurement. Levels of  biomarkers were measured in pretreatment and day 56 serum 
samples. IL-1β (Human IL-1β/IL-1F2 Quantikine ELISA Kit, DLB50, R&D Systems), IL-6 (Quantikine 
ELISA Kit, D6050, R&D Systems), substance P (Substance P Parameter Assay Kit, KGE007, R&D Sys-
tems), and CGRP (human CGRP kit, A05481.96, Bertin Pharma) were quantified by individual compet-
itive ELISAs according to the manufacturer’s instructions. The normal reference range for the proinflam-
matory cytokines and neuropeptides was defined from a population of  10 healthy subjects ranging from 18 
to 50 years of  age.
Statistics. In this trial, 6 patients were enrolled and completed the follow-up. For the secondary out-
comes (clinical parameters), the mean differences from baseline were analyzed, together with a P value and 
a 95% CI (2-tailed paired t test). For the serum biomarkers and the number of  cell infiltrates in the skin, 
Wilcoxon’s signed-rank test was used in a statistical analysis to compare the paired samples of  patients 
before and at different time points during treatment. Two-tailed Student’s t test was used for comparing the 
secondary outcomes (clinical parameters) among age subgroups. Statistical analyses were performed using 
Prism 8 (GraphPad Prism). Statistical significance was defined as P < 0.05.
Study approval. All methods and procedures associated with this study were approved by the institution-
al review board (no. 3-2015-0285) of  Yonsei University College of  Medicine and were performed in com-
pliance with the Declaration of  Helsinki and good clinical practice, as defined under the KFDA regulations 
and the International Conference on Harmonisation guidelines. Prior to inclusion in this study, written 
informed consent was received from all participants or their guardians in case of  pediatric patients. Written 
informed consent was provided for use of  the patient photographs. This clinical trial began in October 
2016 after being approved by the institutional review board of  Gangnam Severance Hospital in December 
2015 and by the KFDA in June 2016. This study was retrospectively registered on Clinicaltrials.gov, as 
institutional review board and KFDA approval is sufficient to initiate a clinical trial and registration on 
1 1
C L I N I C A L  M E D I C I N E
JCI Insight 2021;6(2):e143606  https://doi.org/10.1172/jci.insight.143606
Clinicaltrials.gov is not mandatory in Korea. Our study includes all information, including demographics 
and results, for all patients.
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